Webcast
Natera, Inc. Q4 2018 Earnings Conference Call (Replay)
03/12/19 at 4:30 p.m. ET
Natera, Inc. Q4 2018 Earnings Conference Call
Tuesday, March 12, 2019 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
12/21/16Natera Provides Constellation™ Update
Cloud-based software platform continues to fuel growth and expansion into international markets SAN CARLOS, Calif., Dec. 21, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the availability of a microdeletions testing application for new and existing Constellation licensees worldwide. With the addition of the microdeletions testing capability, Constellation is rapidly becoming a popular delivery platform to access Natera's innovat... 
12/14/16Natera Announces Participation In I-SPY 2 TRIAL For Breast Cancer
Natera to evaluate the effectiveness of liquid biopsy in monitoring breast cancer SAN CARLOS, Calif., Dec. 14, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a collaboration with Dr. Laura van 't Veer  and Dr. Laura Esserman of UCSF and QuantumLeap Healthcare Collaborative to participate in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Im... 
12/01/16The Centers For Medicare And Medicaid Services Establishes 2017 Pricing For Aneuploidy And Microdeletion Testing
SAN CARLOS, Calif., Dec. 1, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA announced today that the Centers for Medicare & Medicaid Services (CMS) released final determinations for the 2017 Clinical Lab Fee Schedule (CLFS), which included determinations for both aneuploidy and microdeletion testing described by Current Procedure Terminology (CPT) codes. CMS decided to cross-walk the aneuploidy (81420) and mic... 
11/22/16Natera to Present at the 28th Annual Piper Jaffray Health Conference
SAN CARLOS, Calif., Nov. 22, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the 28th Annual Piper Jaffray Health Conference in New York on Tuesday, November 29, 2016 at 4:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, will discuss the Company's financial results, business activities and financial outlook. Natera will offer a live audio webcast of the presentatio... 
11/09/16Natera Reports Third Quarter 2016 Financial Results
SAN CARLOS, Calif., Nov. 9, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2016 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $53.9 million in the third quarter of 2016 compared to $44.9 million in the third quarter of 2015, an increase of 20% Acces... 
11/02/16Natera Inc. Announces Third Quarter Earnings Conference Call
SAN CARLOS, Calif., Nov. 2, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended September 30, 2016 after the market close on November 9, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information: ... 
10/13/16Natera Announces Two Poster Presentations on Triploidy and Duchenne Muscular Dystrophy to be Featured at the 2016 American Society for Reproductive Medicine (ASRM) Conference
SAN CARLOS, Calif., Oct. 13, 2016 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present data from Horizon™ carrier screen and Spectrum® pre-implementation genetic screening (PGS) studies at the Annual Meeting of the American Society for Reproductive Medicine (ASRM) Conference in Salt Lake City on Oct. 15-19, 2016. The diverse set of data that will be presented at the conference includes a... 
09/02/16Natera to Present at the Baird 2016 Global Healthcare Conference
SAN CARLOS, Calif., Sept. 2, 2016 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the Baird 2016 Global Healthcare Conference in New York, NY on Thursday, September 8, 2016 at 7:55 a.m. ET. Steve Chapman, Chief Commercial Officer of Natera, will discuss the Company's financial results, business activities and financial outlook. Natera will offer a live audio webcast of the... 
08/04/16Natera Reports Second Quarter 2016 Financial Results
SAN CARLOS, Calif., Aug. 4, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2016 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $52.0 million in the second quarter of 2016 compared to $45.1 million in the second quarter of 2015, an increase of 15% Accessio... 
08/01/16Natera and UCSF Initiate Collaboration to Study DNA Markers of Kidney Transplant Rejection
SAN CARLOS, Calif., Aug. 1, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced a research collaboration with the University of California, San Francisco (UCSF), a leader in renal transplantation medicine in North America, to study the level of donor-derived cell-free DNA (dd-cfDNA) in over several hundred retrospectively banked plasma samples from kidney transplant recipients with and without organ ... 
07/29/16Statement from the American College of Medical Genetics and Genomics Supports the Use of Non-Invasive Prenatal Testing for All Pregnant Women
Natera, Inc. Praises New Practice Guidelines that Advocate NIPT screening for All Women, Regardless of Maternal Age SAN CARLOS, Calif., July 29, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, applauds the new guidelines just released by the American College of Medical Genetics and Genomics (ACMG), supporting the use of non-invasive prenatal tests (NIPT/NIPS) as an optimal, initial ... 
07/28/16Natera Announces Second Quarter Earnings Conference Call
SAN CARLOS, Calif., July 28, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its second quarter ended June 30, 2016 after the market close on August 4, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information ... 
07/18/16Unilabs Selects Natera, Inc.'s Panorama® Non-Invasive Prenatal Test (NIPT), Further Expanding Natera's Global Constellation™ Technology Transfer Business
SAN CARLOS, Calif., July 18, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA),a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, and Swiss-based Unilabs, one of Europe's leading providers of clinical laboratory testing and medical diagnostic imaging services, today announced a Constellation™ technology transfer licensing agreement that enables Unilabs to offer Panorama®, Natera's non-invasive prenatal test (NIPT).  Constellation allows laboratories worldwide ... 
06/30/16Natera Announces that the U.S. Supreme Court Denies Petition to Review '540 Patent Invalidation
SAN CARLOS, Calif., June 30, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced that the U.S. Supreme Court declined to review the Federal Circuit's determination that U.S. Patent 6,258,540 is invalid. The patent had broadly claimed the use of cell-free fetal DNA for genetic testing. Natera filed briefs supporting the Federal Circuit's determination and opposing Supreme Court review. "We are pleased wit... 
06/29/16Natera and Illumina Extend Supply Agreement, Broaden Existing Partnership to Include Oncology Field
SAN CARLOS, Calif., June 29, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the extension of its supply agreement with Illumina, Inc., for up to 10 years. The agreement states that Illumina will supply Natera with sequencing systems and associated consumables for applications including non-invasive prenatal testing, transplant biology and for Natera's oncology diagnostic tests currently in develo... 
05/10/16Natera Reports First Quarter 2016 Financial Results
SAN CARLOS, Calif., May 10, 2016 /PRNewswire/ -- Natera,  Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2016 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $61.9 million in the first quarter of 2016 compared to $47.4 million in the first quarter of 2015, an increase of 31% Accessio... 
05/03/16Natera Announces First Quarter Earnings Conference Call
SAN CARLOS, Calif., May 3, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2016 after the market close on May 10, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information: Ev... 
04/25/16Natera Announces the Appointment of Kimberly Martin, MD as Senior Global Medical Director, Women's Health Franchise
SAN CARLOS, Calif., April 25, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced today that Kimberly Martin, MD, FRCSC, FCCMG, FACOG, FACMG has assumed a new role as the new senior global medical director of Natera's Women's Health franchise. She previously served as the medical director for Reproductive Testing at Natera. Dr. Martin is a nationally recognized expert clinician in the field of ... 
03/11/16American Medical Association Grants New CPT Code for Microdeletion Testing
SAN CARLOS, Calif., March 11, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced the American Medical Association (AMA) has approved Natera's application for a Current Procedural Terminology, or CPT, code for fetal chromosomal microdeletion detection in circulating cell-free fetal DNA in maternal blood.  This code will be effective January 1, 2017. Natera submitted an application for this co... 
03/08/16Natera Reports Fourth Quarter and Fiscal Year 2015 Financial Results
SAN CARLOS, Calif., March 8, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and fiscal year ended December 31, 2015 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $52.9 million in the fourth quarter of 2015 compared to $49.9 million in the fourth quarter of 2014, an incre... 
03/07/16Published Study Demonstrates Natera's Ability to Identify Heterogeneous Cancer Mutations in Patients with Early-Stage Lung Cancer
Analysis of liquid biopsies can detect mutations that may be missed in tumor tissue biopsies SAN CARLOS, Calif., March 7, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a study published in Annals of Oncology showing that Natera's massively multiplexed PCR (mmPCR) technology, coupled with its proprietary algorithms, can detect both ubiquitous (clonal) and heterogeneous (subclonal) tum... 
03/03/16Natera to Present at the Cowen and Company 36th Annual Health Care Conference
SAN CARLOS, Calif., March 3, 2016 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Wednesday, March 9, 2016 at 9:20 a.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, will discuss the Company's financial results, business activities and financial outlook. Natera will offer a live audio webcast of the ... 
03/02/16Natera to Release Fourth Quarter and Fiscal Year 2015 Financial Results
SAN CARLOS, Calif., March 2, 2016 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2015 after the market close on March 8, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information ... 
02/09/16Genetica Now Offering PanoramaTM NIPT in Switzerland via Natera's Constellation™ Software Platform
SAN CARLOS, Calif., Feb. 9, 2016 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Genetica, a leading laboratory for prenatal diagnostics in Switzerland, is now performing the Panorama non-invasive prenatal test (NIPT) at its genetics laboratory in Switzerland. Genetica is leveraging Natera's proprietary technology via Constellation, Natera's cloud-based software platform for clinical genomic analys... 
01/12/16Large-Scale Clinical Study Shows Panorama® Prenatal Screen to be Highly Accurate in Identifying 22q11.2 Deletion Syndrome in a General Population
Clinical evidence supports screening for 22q.11.2 in the general population SAN CARLOS, Calif., Jan. 12, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and analysis of circulating cell-free DNA, today announced the publication of the first major clinical-experience study, which covers the first six months of experience screening for 22q11.2 microdeletion syndrome using the Panorama non-invasive prenatal test (NIPT). The study by Gross, et al. pub... 
Shareholder Tools